Aberdeen Group plc Has $23.25 Million Holdings in Xenon Pharmaceuticals Inc. $XENE

Aberdeen Group plc increased its holdings in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) by 11.1% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 579,145 shares of the biopharmaceutical company’s stock after acquiring an additional 57,653 shares during the period. Aberdeen Group plc owned about 0.75% of Xenon Pharmaceuticals worth $23,253,000 at the end of the most recent quarter.

Several other institutional investors have also recently bought and sold shares of XENE. Assetmark Inc. grew its holdings in shares of Xenon Pharmaceuticals by 6.2% during the third quarter. Assetmark Inc. now owns 22,566 shares of the biopharmaceutical company’s stock worth $906,000 after purchasing an additional 1,316 shares during the last quarter. State of Wyoming grew its holdings in Xenon Pharmaceuticals by 112.8% during the 3rd quarter. State of Wyoming now owns 1,151 shares of the biopharmaceutical company’s stock worth $46,000 after acquiring an additional 610 shares during the last quarter. Principal Financial Group Inc. bought a new stake in Xenon Pharmaceuticals during the 3rd quarter worth about $234,000. Thrivent Financial for Lutherans acquired a new stake in Xenon Pharmaceuticals in the 3rd quarter valued at about $647,000. Finally, Arizona State Retirement System raised its stake in shares of Xenon Pharmaceuticals by 1.8% in the third quarter. Arizona State Retirement System now owns 19,290 shares of the biopharmaceutical company’s stock worth $774,000 after acquiring an additional 334 shares during the last quarter. Institutional investors own 95.45% of the company’s stock.

Insider Activity

In related news, CEO Ian Mortimer sold 40,000 shares of the firm’s stock in a transaction on Friday, January 2nd. The stock was sold at an average price of $44.43, for a total transaction of $1,777,200.00. Following the sale, the chief executive officer owned 6,000 shares of the company’s stock, valued at approximately $266,580. This trade represents a 86.96% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Over the last three months, insiders have sold 65,302 shares of company stock valued at $2,924,128. 4.07% of the stock is owned by insiders.

Xenon Pharmaceuticals Price Performance

Shares of NASDAQ:XENE opened at $41.66 on Wednesday. The firm’s 50 day simple moving average is $42.49 and its 200 day simple moving average is $40.56. Xenon Pharmaceuticals Inc. has a fifty-two week low of $26.74 and a fifty-two week high of $46.60. The company has a market capitalization of $3.22 billion, a price-to-earnings ratio of -10.71 and a beta of 0.96.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on XENE. Wells Fargo & Company raised their price target on shares of Xenon Pharmaceuticals from $44.00 to $48.00 and gave the company an “overweight” rating in a report on Thursday, December 11th. Chardan Capital upgraded Xenon Pharmaceuticals to a “strong-buy” rating in a research report on Wednesday, November 19th. JPMorgan Chase & Co. boosted their target price on Xenon Pharmaceuticals from $60.00 to $62.00 and gave the stock an “overweight” rating in a research report on Friday, January 9th. Royal Bank Of Canada upped their price target on Xenon Pharmaceuticals from $55.00 to $58.00 and gave the company an “outperform” rating in a research note on Tuesday, November 4th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Xenon Pharmaceuticals in a research report on Friday, January 9th. Two analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Xenon Pharmaceuticals currently has an average rating of “Buy” and a consensus target price of $54.73.

Xenon Pharmaceuticals Profile

Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company’s pipeline comprises multiple preclinical and clinical programs.